This is a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.
This trial has suspended patient recruitment.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Enrollment: 291 patients (estimated)View More
December 11, 2021
Results: Of 291 randomized pts (194 to Ven and 97 to Placebo), 33 pts were receiving ongoing treatment (28 with Ven and 5 with Placebo) as of the final OS analysis data cutoff (March 15, 2021). At a median follow-up of 45.6 months, there were 78 (40%) deaths in the Ven arm versus 36 (37%) in the Placebo arm. Updated PFS and OS among all pts and those with t(11;14) or high BCL2 expression are shown in the Table. Among all pts, the median PFS per investigator was 23.4 months in the Ven arm versus 11.4 months in the Placebo arm (HR, 0.58 [95% CI, 0.43–0.78]). In pts with t(11;14), the median PFS was 36.8 months in the Ven arm versus 9.3 months in the Placebo arm (HR, 0.12 [95% CI, 0.03–0.44]). In pts with high BCL2, the median PFS was 30.1 months in the Ven arm versus 9.9 months in the Placebo arm (HR, 0.37 [95% CI, 0.21–0.64]). Median OS was not reached in the Ven or Placebo arm among all pts (HR, 1.19 [95% CI, 0.80–1.77]), pts with t(11;14) (HR, 0.61 [95% CI, 0.16–2.32]), pts with high BCL2 (HR, 0.70 [95% CI, 0.32–1.51]), and pts with t(11;14) or high BCL2 (HR, 0.82 [95% CI, 0.40–1.70]).
The most common treatment-emergent adverse events (AEs) with Ven (versus Placebo) were diarrhea (60% versus 50%), nausea (38% versus 23%), and constipation (35% versus 31%). The most common Grade 3/4 AEs (Ven versus Placebo) were thrombocytopenia (16% versus 30%), neutropenia (23% versus 8%), pneumonia (19% versus 13%), anemia (16% versus 15%), and diarrhea (15% versus 11%). Serious AEs occurred in 57% of Ven- and 55% of Placebo-treated pts, with serious infections and infestations occurring in 35% and 29% of pts, respectively. Overall, 26% of pts in the Ven arm and 11% of pts in the Placebo arm experienced an AE leading to Ven or Placebo discontinuation. AEs led to 12 deaths in the Ven arm, with 9 of these deaths due to serious infection; an AE led to 1 death in the Placebo arm. A total of 16 (6%) treatment-emergent deaths occurred (14 [7%] with Ven and 2 [2%] with Placebo), with 3 of these deaths due to disease progression (2 [1%] with Ven and 1 [1%] with Placebo).
View all clinical trial locations sorted by state.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message